NASDAQ:BGNE - Beigene Stock Price, Forecast & News

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Beigene Ltd (NASDAQ:BGNE) released its earnings results on Tuesday, November, 12th. The company reported ($5.11) earnings per share for the quarter, missing analysts' consensus estimates of ($3.56) by $1.55. The firm had revenue of $50.14 million for the quarter, compared to analysts' expectations of $65.43 million. Beigene had a negative net margin of 192.75% and a negative return on equity of 53.11%. The firm's quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.53) EPS. View Beigene's Earnings History.

Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Beigene.

10 Wall Street analysts have issued 1-year price objectives for Beigene's stock. Their forecasts range from $165.00 to $230.00. On average, they anticipate Beigene's stock price to reach $209.38 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for Beigene.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene.

News articles about BGNE stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Beigene earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Beigene.

Some companies that are related to Beigene include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL) and Teva Pharmaceutical Industries (TEVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), TENCENT HOLDING/ADR (TCEHY), Netflix (NFLX), Sarepta Therapeutics (SRPT), Canopy Growth (CGC), Gilead Sciences (GILD) and Roku (ROKU).

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Beigene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Meag Munich Ergo Kapitalanlagegesellschaft MBH (0.04%), Rhenman & Partners Asset Management AB (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), JGP Global Gestao de Recursos Ltda. (0.01%), Mckinley Capital Management LLC Delaware (0.01%) and IFM Investors Pty Ltd (0.00%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware and IFM Investors Pty Ltd. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View Insider Buying and Selling for Beigene.

BGNE stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Zurcher Kantonalbank Zurich Cantonalbank and JGP Global Gestao de Recursos Ltda.. View Insider Buying and Selling for Beigene.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BGNE stock can currently be purchased for approximately $163.56.

Beigene has a market capitalization of $9.99 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe.View Additional Information About Beigene.

The official website for Beigene is http://www.beigene.com/.

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]